Pasithea Therapeutics KTTA
NASDAQ KTTA
$0.40 -0.05 (-11.11%)
At close: Oct 23, 2026 · 4:00 PM EDT

Pasithea Therapeutics (KTTA) Gains from Sales and Divestitures (2025)

Updated

Pasithea Therapeutics (KTTA) recorded Gains from Sales and Divestitures of $65,048 in FY2023.

Analysis

Pasithea Therapeutics (KTTA) Gains from Sales and Divestitures (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Pasithea Therapeutics 13.37 Mn -142.02 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -7,171.00
API Access

Pasithea Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KTTA&period=max&api_key=YOUR_API_KEY